Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Val Gebski

Showing results (201-210 of 248) with videos related to

Pageof 25
Sort By:
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
The Lancet. Diabetes & Endocrinology|March 3, 2018
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD studyBoris Waldman, Jean-Claude Ansquer, David R Sullivan, et al.
BMJ Open|September 3, 2021
Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trialTony Butler, Peter W Schofield, Lee Knight, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
The Lancet. Oncology|June 6, 2020
Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trialMichael Frumovitz, Andreas Obermair, Robert L Coleman, et al.
Eclinicalmedicine|December 16, 2025
Sertraline to reduce recidivism in impulsive violent offenders (ReINVEST): a randomised double blind clinical trialTony Butler, Emaediong I Akpanekpo, Lee Knight, et al.
Diabetes Research and Clinical Practice|February 23, 2026
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudyAndrzej S Januszewski, Michael L H Huang, Abubakar Mangani, et al.
The New England Journal of Medicine|September 16, 2024
Preoperative Chemoradiotherapy for Resectable Gastric CancerTrevor Leong, B Mark Smithers, Michael Michael, et al.
The Lancet. Oncology|July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedlander, Val Gebski, Emma Gibbs, et al.
Journal of the National Cancer Institute|April 19, 2013
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysisChee Khoon Lee, Chris Brown, Richard J Gralla, et al.
Pageof 25

Showing results (201-210 of 248) with videos related to

Sort By:
Pageof 25
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
The Lancet. Diabetes & Endocrinology|March 3, 2018
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD studyBoris Waldman, Jean-Claude Ansquer, David R Sullivan, et al.
BMJ Open|September 3, 2021
Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trialTony Butler, Peter W Schofield, Lee Knight, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
The Lancet. Oncology|June 6, 2020
Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trialMichael Frumovitz, Andreas Obermair, Robert L Coleman, et al.
Eclinicalmedicine|December 16, 2025
Sertraline to reduce recidivism in impulsive violent offenders (ReINVEST): a randomised double blind clinical trialTony Butler, Emaediong I Akpanekpo, Lee Knight, et al.
Diabetes Research and Clinical Practice|February 23, 2026
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudyAndrzej S Januszewski, Michael L H Huang, Abubakar Mangani, et al.
The New England Journal of Medicine|September 16, 2024
Preoperative Chemoradiotherapy for Resectable Gastric CancerTrevor Leong, B Mark Smithers, Michael Michael, et al.
The Lancet. Oncology|July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedlander, Val Gebski, Emma Gibbs, et al.
Journal of the National Cancer Institute|April 19, 2013
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysisChee Khoon Lee, Chris Brown, Richard J Gralla, et al.
Pageof 25